Clinical Trial

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated March 20, 2026 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.
Protocol Amendment History 21 amendments
This ClinicalTrials.gov record has been amended 21 times since 2021-04-01; most recent amendment 2026-03-18.
Status change: Active, Not Recruiting → Recruiting 2024-07-25
Status change: Recruiting → Active, Not Recruiting 2023-11-03
Trial Details
NCT Number NCT04830137
Lead Sponsor Nurix Therapeutics, Inc.
Conditions Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia (WM), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL), Diffuse Large B-cell Lymphoma (DLBCL), Primary Central Nervous System Lymphoma (PCNSL)
Enrollment 248 participants
Start Date 2021-05-05
Primary Completion 2026-05 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-03-20